S&P 500   4,622.44 (+0.39%)
DOW   36,404.93 (+0.43%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.35 (-2.22%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.62 (-1.73%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.34%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)
S&P 500   4,622.44 (+0.39%)
DOW   36,404.93 (+0.43%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.35 (-2.22%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.62 (-1.73%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.34%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)
S&P 500   4,622.44 (+0.39%)
DOW   36,404.93 (+0.43%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.35 (-2.22%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.62 (-1.73%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.34%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)
S&P 500   4,622.44 (+0.39%)
DOW   36,404.93 (+0.43%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.35 (-2.22%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.62 (-1.73%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.34%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)

Vertex Pharmaceuticals (VRTX) Stock Price, News & Analysis

$356.29
+6.14 (+1.75%)
(As of 04:25 PM ET)
Compare
Today's Range
$351.44
$357.52
50-Day Range
$343.00
$385.76
52-Week Range
$282.21
$387.42
Volume
1.25 million shs
Average Volume
1.20 million shs
Market Capitalization
$91.81 billion
P/E Ratio
26.73
Dividend Yield
N/A
Price Target
$377.13

Vertex Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.63 Rating Score
Upside/​Downside
5.6% Upside
$377.13 Price Target
Short Interest
Healthy
0.98% of Float Sold Short
Dividend Strength
N/A
Sustainability
-3.12
Upright™ Environmental Score
News Sentiment
0.92mentions of Vertex Pharmaceuticals in the last 14 days
Based on 26 Articles This Week
Insider Trading
Selling Shares
$17.62 M Sold Last Quarter
Proj. Earnings Growth
10.63%
From $13.73 to $15.19 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.56 out of 5 stars

Medical Sector

121st out of 945 stocks

Pharmaceutical Preparations Industry

43rd out of 434 stocks


VRTX stock logo

About Vertex Pharmaceuticals Stock (NASDAQ:VRTX)

Vertex Pharmaceuticals Incorporated, an American biopharmaceutical company headquartered in Boston, Massachusetts, was founded in 1989 by Joshua Boger and Kevin J. Kinsella with a vision to revolutionize disease treatments through rational drug design. Their mission is to "transform the way serious diseases are treated," and they have made significant strides in achieving this goal. The company specializes in researching, developing, and commercializing innovative therapies for various medical conditions, primarily focusing on cystic fibrosis. Using cutting-edge science and technology, Vertex has become a leading player in the biotech industry, particularly in the field of precision medicine.

Vertex has overcome challenges and achieved milestones, chronicled in Barry Werth's book "The Billion-Dollar Molecule." Over the years, the company's research and development efforts have primarily targeted viral infections, inflammatory and autoimmune disorders, cancer, and other specialty diseases. Vertex's flagship products are dedicated to treating cystic fibrosis, a genetic condition affecting the respiratory and digestive systems. Notable among these are Kalydeco, the first FDA-approved drug addressing the underlying cause of cystic fibrosis for specific gene mutations, Orkambi, a combination drug for patients with the most common cystic fibrosis mutation (F508del), Symdeko, a dual combination treatment for certain gene mutations and Trikafta, a groundbreaking triple-combination therapy for cystic fibrosis.

The company's target market consists of patients suffering from serious diseases, especially those with cystic fibrosis and other genetic disorders. Vertex's therapies are designed to cater to specific gene mutations, offering personalized and precision medicine approaches. Key customers include patients with cystic fibrosis and their families, healthcare providers specializing in genetic diseases and health systems, and insurers providing access to these life-changing therapies. Vertex Pharmaceuticals has achieved significant financial growth in recent years, reflecting its successful drug development efforts. Impressive revenue metrics and robust earnings metrics indicate the company's ability to translate its research into profitable treatments efficiently. The company's strong profit margin metrics also showcase its effective financial management.

The positive financial performance has driven the company's stock price upwards, reflecting investor confidence in Vertex's ability to deliver innovative therapies and capitalize on unmet medical needs. The company's strong financials, expanding product pipeline, and contributions to cystic fibrosis treatment have justified its favorable valuation compared to industry peers. Vertex Pharmaceuticals' successful development and commercialization of Trikafta have been key drivers behind the company's positive valuation and investor sentiment. The drug's significant impact on patients and its potential for continued growth have attracted investors seeking exposure to the dynamic biopharmaceutical sector.

As Vertex explores gene-editing therapies in collaboration with CRISPR Therapeutics and Arbor Biotechnologies, investors view the company as a strategic player in addressing significant unmet medical needs. The company's commitment to research and development further solidifies investor confidence in its long-term prospects.

Vertex Pharmaceuticals has demonstrated resilient stock performance. Investors recognize the company's value as a pioneer in the biotech industry, with a focus on precision medicine and transformative therapies. The company's dedication to research and its successful commercialization of existing drugs underscores its strategic positioning in the market.

As Vertex continues to expand its product pipeline and explore new treatment avenues, investors remain optimistic about the company's growth potential. The company's innovative research collaborations, particularly in gene-editing therapies, are expected to drive further positive investor sentiment. In the broader industry, Vertex Pharmaceuticals is well-positioned relative to its peers. Its specialization in precision medicine and groundbreaking therapies for genetic diseases sets it apart, giving the company a competitive advantage. Vertex's successful track record and commitment to addressing unmet medical needs further reinforce its strong position in the market.

While Vertex Pharmaceuticals has achieved significant milestones, the company faces certain risks and challenges. Regulatory hurdles, competitive pressures, and the need for continued investment in research and development are potential factors that may impact its future growth. However, the company's risk management strategies and prudent financial management are designed to mitigate potential risks and position Vertex for continued success. As the company continues to innovate and expand its product portfolio, it is expected to maintain its strong position in the biopharmaceutical industry.

VRTX Stock Price History

VRTX Stock News Headlines

MarketBeat Week in Review – 11/6 - 11/10 (VRTX)
Stocks closed the week with a strong rally, but the rally may reverse when investors get the latest information about inflation and retail stocks next week
Lithium Discovery So BIG You Can't Miss it, Even From Space
With the green energy transition well underway, lithium demand is rapidly outpacing projected supply. While companies frantically search for new sources of this critical metal, one small company is sitting on a massive claim in North America - So big in fact that it can clearly be seen from space!
Sickle cell gene editing faces market hurdles: Analyst
Bull of the Day: CRISPR Therapeutics (CRSP)
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Forget the "Magnificent Seven": Buy This Stock Instead
5 Unstoppable Trends to Invest $1,000 in for 2024
Hold Rating on Vertex Pharmaceuticals Pending Clinical Trial Outcomes
3 No-Brainer Growth Stocks to Buy in December
Vertex (VRTX) Gets EU Nod for Kaftrio Use in 2-5 Year Kids
Insider Sell Analysis: EVP & CFO Charles F. Wagner Jr. ...
See More Headlines
Receive VRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
12/11/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/06/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:VRTX
CUSIP
92532F10
Employees
4,800
Year Founded
1989

Price Target and Rating

Average Stock Price Target
$376.43
High Stock Price Target
$456.00
Low Stock Price Target
$296.00
Potential Upside/Downside
+7.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
19 Analysts

Profitability

Net Income
$3.32 billion
Pretax Margin
44.63%

Debt

Sales & Book Value

Annual Sales
$8.93 billion
Cash Flow
$13.99 per share
Book Value
$54.20 per share

Miscellaneous

Free Float
256,652,000
Market Cap
$90.23 billion
Optionable
Optionable
Beta
0.42

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Should I Buy Vertex Pharmaceuticals Stock? VRTX Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Vertex Pharmaceuticals was last updated on Sunday, December 10, 2023 at 7:49 PM.

Pros

Here are some ways that investors could benefit from investing in Vertex Pharmaceuticals Incorporated:

  • Strong financial performance: Vertex Pharmaceuticals had a return on equity of 22.79% and a net margin of 35.94%, indicating a profitable business.
  • Revenue growth: The company's revenue was up 6.4% compared to the same quarter last year, suggesting a positive trend.
  • Earnings per share: Analysts anticipate that Vertex Pharmaceuticals will post 13.61 earnings per share for the current year, indicating potential profitability.
  • Insider transactions: Insiders have sold 47,911 shares of company stock worth $17,624,025 in the last ninety days, suggesting confidence in the company's future.
  • Positive analyst ratings: Analysts have given Vertex Pharmaceuticals an "overweight" rating and raised price targets, indicating positive sentiment towards the stock.

Cons

Investors should be bearish about investing in Vertex Pharmaceuticals Incorporated for these reasons:

  • Stock price volatility: The stock price of Vertex Pharmaceuticals may experience fluctuations, which could pose risks to investors.
  • Competition in the biotech sector: Vertex Pharmaceuticals operates in a highly competitive industry, which may impact its market position and profitability.
  • Regulatory challenges: The pharmaceutical industry is subject to strict regulations, and any changes in regulations could affect Vertex Pharmaceuticals' operations.
  • Dependency on key products: Vertex Pharmaceuticals' success is heavily reliant on the performance of its key products, and any setbacks or failures could impact its financial performance.
  • Market uncertainties: The biotech sector is influenced by various market factors, including economic conditions and investor sentiment, which could affect the stock price of Vertex Pharmaceuticals.














VRTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Vertex Pharmaceuticals stock right now?

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 7 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VRTX shares.
View VRTX analyst ratings
or view top-rated stocks.

What is Vertex Pharmaceuticals' stock price target for 2024?

19 analysts have issued 1 year target prices for Vertex Pharmaceuticals' shares. Their VRTX share price targets range from $296.00 to $456.00. On average, they predict the company's stock price to reach $377.13 in the next year. This suggests a possible upside of 5.6% from the stock's current price.
View analysts price targets for VRTX
or view top-rated stocks among Wall Street analysts.

How have VRTX shares performed in 2023?

Vertex Pharmaceuticals' stock was trading at $288.78 at the beginning of the year. Since then, VRTX stock has increased by 23.7% and is now trading at $357.26.
View the best growth stocks for 2023 here
.

When is Vertex Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 6th 2024.
View our VRTX earnings forecast
.

How were Vertex Pharmaceuticals' earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released its quarterly earnings data on Monday, November, 6th. The pharmaceutical company reported $4.08 EPS for the quarter, topping the consensus estimate of $3.53 by $0.55. The pharmaceutical company had revenue of $2.48 billion for the quarter, compared to the consensus estimate of $2.50 billion. Vertex Pharmaceuticals had a net margin of 35.94% and a trailing twelve-month return on equity of 22.79%. The firm's quarterly revenue was up 6.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.62 earnings per share.
Read the conference call transcript
.

What is Reshma Kewalramani's approval rating as Vertex Pharmaceuticals' CEO?

31 employees have rated Vertex Pharmaceuticals Chief Executive Officer Reshma Kewalramani on Glassdoor.com. Reshma Kewalramani has an approval rating of 76% among the company's employees.

What other stocks do shareholders of Vertex Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), Salesforce (CRM), Netflix (NFLX), Intel (INTC) and PayPal (PYPL).

Who are Vertex Pharmaceuticals' major shareholders?

Vertex Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (5.57%), Wellington Management Group LLP (2.53%), Massachusetts Financial Services Co. MA (1.51%), Jennison Associates LLC (1.47%), Loomis Sayles & Co. L P (1.23%) and Clearbridge Investments LLC (1.14%). Insiders that own company stock include Amit Sachdev, Bastiano Sanna, Bruce I Sachs, Carmen Bozic, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Jonathan Biller, Joy Liu, Kristen Ambrose, Lloyd Carney, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Sangeeta N Bhatia, Stuart A Arbuckle and Yuchun Lee.
View institutional ownership trends
.

How do I buy shares of Vertex Pharmaceuticals?

Shares of VRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Vertex Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Vertex Pharmaceuticals: Aurora Biosciences Corporation, Exonics Therapeutics, Semma Therapeutics, The Vertex Foundation Inc., Torreyana Insurance Company Inc., V2X, Vertex Farmaceutica do Brasil LTDA, Vertex Holdings Inc., Vertex Pharmaceuticals (Australia) Pty. Ltd., Vertex Pharmaceuticals (CH) GmbH, Vertex Pharmaceuticals (Canada) Incorporated, Vertex Pharmaceuticals (Cayman 509) Limited, Vertex Pharmaceuticals (Cayman 765) Limited, Vertex Pharmaceuticals (Cayman 787) Limited, Vertex Pharmaceuticals (Cayman III) Limited, Vertex Pharmaceuticals (Cayman) Limited, Vertex Pharmaceuticals (Czech Republic) s.r.o, Vertex Pharmaceuticals (Delaware) LLC, Vertex Pharmaceuticals (Distribution) Incorporated, Vertex Pharmaceuticals (Europe) Limited, Vertex Pharmaceuticals (France) SAS, Vertex Pharmaceuticals (Germany) GmbH, Vertex Pharmaceuticals (Ireland) Limited, Vertex Pharmaceuticals (Italy) S.r.L., Vertex Pharmaceuticals (Netherlands) B.V., Vertex Pharmaceuticals (Poland) sp. z.o.o, Vertex Pharmaceuticals (Portugal), Vertex Pharmaceuticals (Puerto Rico) LLC, Vertex Pharmaceuticals (San Diego) LLC, Vertex Pharmaceuticals (Singapore) Pte. Ltd., Vertex Pharmaceuticals (Spain) S.L., Vertex Pharmaceuticals (Sweden) AB, Vertex Pharmaceuticals (U.K.) Limited, Vertex Pharmaceuticals GmbH, Vertex Pharmaceuticals Single Member Societe Anonyme, and Vertex Securities Corporation.
Read More
This page (NASDAQ:VRTX) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -